Dr Price Jackson
Honorary Conjoint Fellow
The Sir Peter MacCallum Department of Oncology
79 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Fully automated deep learning-based algorithm for contouring primary malignancy on PSMA PET/CT: results from the proPSMA trial in men with intermediate to high-risk prostate cancer
DOI: 10.1016/j.eanmj.2026.1002192026
Journal article
Deep learning and radiomics models in patients with advanced non-small cell lung cancer treated with immunotherapy combined with stereotactic radiotherapy.
DOI: 10.1038/s41598-026-53520-52026
Journal article
Thrombotic Microangiopathy in Patients Treated with 177Lu-PSMA Combination Therapies.
DOI: 10.2967/jnumed.126.2720852026
Journal article
First Images on a Next-Generation Extended-Field-of-View Digital Bismuth Germanium Oxide Total-Body PET/CT.
DOI: 10.2967/jnumed.125.2719952026
Journal article
Pulling Together: A 5-Year Plan to Improve Theranostic Outcomes by Improving the Accuracy of Dosimetry-An FNIH Joint Academic, Clinical, and Industrial Collaboration.
DOI: 10.2967/jnumed.125.2716652026
Journal article
P0350 Biochemical recurrence and safety in patients with high-risk localised prostate cancer treated with [177Lu] Lu-PSMA-617 prior to prostatectomy: Follow-up of the LuTectomy trial
DOI: 10.1016/s0302-2838(26)01246-72018
Journal article
Cold kit for prostate-Specific membrane antigen (PSMA) PET imaging: Phase 1 study of 68Ga-Tris (Hydroxypyridinone)-PSMA PET/CT in patients with prostate cancer
DOI: 10.2967/jnumed.117.199554
RECENT SCHOLARLY WORKS
2025
Journal article
Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis
DOI: 10.2967/jnumed.125.2708042025
Journal article
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
DOI: 10.1016/S1470-2045(25)00559-52025
Conference Proceedings
2386P A phase I/II trial of combined Radium-223 and Lutetium-177 PSMA-I&T in patients with metastatic castration-resistant prostate cancer (mCRPC): First analysis of the AlphaBet trial
DOI: 10.1016/j.annonc.2025.08.30022025
Journal article
Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials
DOI: 10.2967/jnumed.125.269640